Mónica Giménez1, Jesús Pujol2, Zahid Ali1, Marina López-Solà1, Oren Contreras-Rodríguez1, Joan Deus1, Héctor Ortiz1, Carles Soriano-Mas1, Jone Llorente-Onaindia1, Jordi Monfort1. 1. From the MRI Research Unit, CRC Mar; Rheumatology Department, Hospital del Mar; Centro Investigación Biomédica en Red de Salud Mental, CIBERSAM G21; Department of Clinical and Health Psychology, Autonomous University of Barcelona; Bellvitge Biomedical Research Institute, Psychiatry Department, Bellvitge University Hospital, CYBERSAM; Cell Research Group in Inflammation and Cartilage, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain; Neurosciences Centers of Excellence for Drug Discovery (CEDD), GlaxoSmithKline, London, UK; Pfizer, Neusentis, Cambridge, UK; Department of Psychology and Neuroscience, University of Colorado, Boulder, Colorado, USA.M. Giménez, PhD; O. Contreras-Rodríguez, PhD; H. Ortiz, MsC, MRI Research Unit, CRC Mar, Hospital del Mar; J. Pujol, MD, MRI Research Unit, CRC Mar, Hospital del Mar, Centro Investigación Biomédica en Red de Salud Mental, CIBERSAM G21; Z. Ali, PhD, Neurosciences CEDD, GlaxoSmithKline; M. López-Solà, PhD, MRI Research Unit, CRC Mar, Hospital del Mar, Department of Psychology and Neuroscience, University of Colorado; J. Deus, PhD, MRI Research Unit, CRC Mar, Hospital del Mar, Department of Clinical and Health Psychology, Autonomous University of Barcelona; C. Soriano-Mas, PhD, Bellvitge Biomedical Research Institute-IDIBELL, Psychiatry Department, Bellvitge University Hospital, CIBERSAM; J. Llorente-Onaindia, MsC; J. Monfort, MD, PhD, Rheumatology Department, Hospital del Mar, Cell Research Group in Inflammation and Cartilage, Institut Hospital del Mar d'Investigacions Mèdiques. 2. From the MRI Research Unit, CRC Mar; Rheumatology Department, Hospital del Mar; Centro Investigación Biomédica en Red de Salud Mental, CIBERSAM G21; Department of Clinical and Health Psychology, Autonomous University of Barcelona; Bellvitge Biomedical Research Institute, Psychiatry Department, Bellvitge University Hospital, CYBERSAM; Cell Research Group in Inflammation and Cartilage, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain; Neurosciences Centers of Excellence for Drug Discovery (CEDD), GlaxoSmithKline, London, UK; Pfizer, Neusentis, Cambridge, UK; Department of Psychology and Neuroscience, University of Colorado, Boulder, Colorado, USA.M. Giménez, PhD; O. Contreras-Rodríguez, PhD; H. Ortiz, MsC, MRI Research Unit, CRC Mar, Hospital del Mar; J. Pujol, MD, MRI Research Unit, CRC Mar, Hospital del Mar, Centro Investigación Biomédica en Red de Salud Mental, CIBERSAM G21; Z. Ali, PhD, Neurosciences CEDD, GlaxoSmithKline; M. López-Solà, PhD, MRI Research Unit, CRC Mar, Hospital del Mar, Department of Psychology and Neuroscience, University of Colorado; J. Deus, PhD, MRI Research Unit, CRC Mar, Hospital del Mar, Department of Clinical and Health Psychology, Autonomous University of Barcelona; C. Soriano-Mas, PhD, Bellvitge Biomedical Research Institute-IDIBELL, Psychiatry Department, Bellvitge University Hospital, CIBERSAM; J. Llorente-Onaindia, MsC; J. Monfort, MD, PhD, Rheumatology Department, Hospital del Mar, Cell Research Group in Inflammation and Cartilage, Institut Hospital del Mar d'Investigacions Mèdiques. 21404jpn@comb.cat.
Abstract
OBJECTIVE: The aim of our study was to investigate the effects of naproxen, an antiinflammatory analgesic drug, on brain response to painful stimulation on the affected knee in chronic osteoarthritis (OA) using functional magnetic resonance imaging (fMRI) in a double-blind, placebo-controlled study. METHODS: A sample of 25 patients with knee OA received naproxen (500 mg), placebo, or no treatment in 3 separate sessions in a randomized manner. Pressure stimulation was applied to the medial articular interline of the knee during the fMRI pain sequence. We evaluated subjective pain ratings at every session and their association with brain responses to pain. An fMRI control paradigm was included to discard global brain vascular effects of naproxen. RESULTS: We found brain activation reductions under naproxen compared to no treatment in different cortical and subcortical core pain processing regions (p≤0.001). Compared to placebo, naproxen triggered an attenuation of amygdala activation (p=0.001). Placebo extended its attenuation effects beyond the classical pain processing network (p≤0.001). Subjective pain scores during the fMRI painful task differed between naproxen and no treatment (p=0.037). Activation attenuation under naproxen in different regions (i.e., ventral brain, cingulate gyrus) was accompanied by an improvement in the subjective pain complaints (p≤0.002). CONCLUSION:Naproxen effectively reduces pain-related brain responses involving different regions and the attenuation is related to subjective pain changes. Our current work yields further support to the utility of fMRI to objectify the acute analgesic effects of a single naproxen dose in patients affected by knee OA. The trial was registered at the EuropeanClinicalTrials Database, "EudraCT Number 2008-004501-33".
RCT Entities:
OBJECTIVE: The aim of our study was to investigate the effects of naproxen, an antiinflammatory analgesic drug, on brain response to painful stimulation on the affected knee in chronic osteoarthritis (OA) using functional magnetic resonance imaging (fMRI) in a double-blind, placebo-controlled study. METHODS: A sample of 25 patients with knee OA received naproxen (500 mg), placebo, or no treatment in 3 separate sessions in a randomized manner. Pressure stimulation was applied to the medial articular interline of the knee during the fMRI pain sequence. We evaluated subjective pain ratings at every session and their association with brain responses to pain. An fMRI control paradigm was included to discard global brain vascular effects of naproxen. RESULTS: We found brain activation reductions under naproxen compared to no treatment in different cortical and subcortical core pain processing regions (p≤0.001). Compared to placebo, naproxen triggered an attenuation of amygdala activation (p=0.001). Placebo extended its attenuation effects beyond the classical pain processing network (p≤0.001). Subjective pain scores during the fMRI painful task differed between naproxen and no treatment (p=0.037). Activation attenuation under naproxen in different regions (i.e., ventral brain, cingulate gyrus) was accompanied by an improvement in the subjective pain complaints (p≤0.002). CONCLUSION:Naproxen effectively reduces pain-related brain responses involving different regions and the attenuation is related to subjective pain changes. Our current work yields further support to the utility of fMRI to objectify the acute analgesic effects of a single naproxen dose in patients affected by knee OA. The trial was registered at the EuropeanClinicalTrials Database, "EudraCT Number 2008-004501-33".
Entities:
Keywords:
MAGNETIC RESONANCE IMAGING; NAPROXEN; OSTEOARTHRITIS; PAIN
Authors: Jaymin Upadhyay; Christian Geber; Richard Hargreaves; Frank Birklein; David Borsook Journal: Neurosci Biobehav Rev Date: 2017-08-12 Impact factor: 8.989
Authors: Marina López-Solà; Choong-Wan Woo; Jesus Pujol; Joan Deus; Ben J Harrison; Jordi Monfort; Tor D Wager Journal: Pain Date: 2017-01 Impact factor: 7.926
Authors: Diane Reckziegel; Helen Bailey; William J Cottam; Christopher R Tench; Ravi P Mahajan; David A Walsh; Roger D Knaggs; Dorothee P Auer Journal: BMJ Open Date: 2017-06-26 Impact factor: 2.692